Dataset Information

NLRP3/CCR2 Blockade by Arglabin and Its Derivative Suppresses Myeloid-Driven Immunosuppression and Potentiates Anti-PD-L1 Immunotherapy in Hepatocellular Carcinoma

ABSTRACT: Background Hepatocellular carcinoma (HCC) evolves within an NLRP3-enriched immunosuppressive microenvironment where myeloid-derived suppressor cells (MDSCs) orchestrate T cell dysfunction. While the NLRP3 inhibitor arglabin (Arg) shows clinical anti-tumor activity, its immune-specific targets and mechanisms remain undefined. Method NLRP3 and CCR2 expressions were explored in tumor tissues from 14 HCC patients. Overall survival and the correlation between two proteins in HCC patients were analyzed using GEO and TCGA databases. Molecular interactions were validated through CETSA, SPR, and LC-MS/MS. In vivo antitumor efficacy was assessed in syngeneic murine models of H22 (BALB/c) and Hepa1-6 (C57BL/6) liver cancer cells. Functional analyses were conducted using CCK8, MDSC depletion (anti-Gr-1 antibody) and transwell invasion assays. Flow cytometry characterized TME composition, while in vivo bioluminescent imaging monitored tumor burden. Transcriptomic profiling of ChIP-qPCR deciphered CCR2 regulatory mechanisms. Structural optimization yielded compound C2, evaluated through pharmacokinetic studies and mechanism validation. Results NLRP3 overexpression in HCC patients correlated with reduced survival. Arg covalently bound to NLRP3 at Cys280 (KD = 16.32 nM), suppressing CCR2 transcription via non-canonical NLRP3 activity——independent of inflammasome activation. This myeloid-specific mechanism reduced MDSC infiltration (61.20% decrease vs control) while expanding cytotoxic CD8+ T cells (2.4-fold increase), achieving 56.42% tumor growth inhibition (TGI) in immunocompetent models. Synergy with anti-PD-L1 therapy enhanced TGI to 96.99%. Structural optimization generated orally C2, which maintained CCR2 suppression efficacy and MDSC suppression, and achieved 93.86% TGI at 18 mg/kg. Conclusion We redefine NLRP3 as a transcriptional regulator governing CCR2-dependent trafficking of MDSCs and identify Arg as a covalent NLRP3 inhibitor. The NLRP3/CCR2 axis emerges as a druggable target to alleviate immunosuppression in HCC, with Arg-derived C2 demonstrating significant clinical translation potential. This work establishes a framework for developing natural product-derived immunomodulators, which exhibit synergistic efficacy with immune checkpoint inhibitors to overcome resistance in cancer immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE293568 | GEO | 2026/04/01

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that accumulate in the tumor microenvironment of most cancer patients. There MDSCs suppress both adaptive and innate immune responses, hindering immunotherapies. Moreover, many cancers are accompanied by inflammation, a processes that further intensifies MDSC suppressive activity, causing aggressive tumor progression and metastasis. MDSCs collected from tumor-bearing mice profusely release nano-scale membrane-bound extracellular vesicles, called exosomes, which carry biologically active proteins between cells and contribute directly to the immune suppressive functions of MDSC. Many studies on other cell types have shown that exosomes may also carry microRNAs (miRNAs) and messenger RNAs (mRNAs) which can also be transferred to surrounding and distant cells. However, to the best of our knowledge, the miRNA and mRNA cargo of MDSC-derived exosomes has not yet been interrogated. This study aims to identify and quantify the cargo of MDSC and their immunosuppressive exosomes to gather knowledge that can offer insights on the mechanisms by which MDSCs contribute to immune suppression, focusing on the role of exosomes as intercellular communication mediators in the tumor microenvironment. In order to achieve our objective a well-established mouse model based on a conventional mammary carcinoma (4T1 cells) and heightened inflammation (4T1 transduced to express the cytokine interleukin-1b) was used. We provide evidence that MDSC-derived exosomes carry proteins, mRNAs and miRNAs. Relative quantitation demonstrated quantitative differences between the exosome cargo and the cargo of their parental cells, supporting the hypothesis that selective loading into the exosomes is possible. Additionally, quantitative and functional analyses of the exosome cargo generated under conventional and heightened inflammation conditions are consistent with clinical observations that inflammation is linked to cancer development.

Project description:Aging results in enhanced myelopoiesis, which is associated with an increased prevalence of myeloid leukemias and the production of myeloid-derived suppressor cells (MDSCs). Tristetraprolin (TTP) is an RNA binding protein that regulates immune-related cytokines and chemokines by destabilizing target mRNAs. As TTP expression is known to decrease with age in myeloid cells, we used TTP-deficient (TTPKO) mice to model aged mice to study TTP regulation in age-related myelopoiesis. Both TTPKO and myeloidspecific TTPKO (cTTPKO) mice had significant increases in both MDSC subpopulations M-MDSCs (CD11b+Ly6ChiLy6G-) and PMN-MDSCs (CD11b+Ly6CloLy6G+), as well as macrophages (CD11b+F4/80+) in the spleen and mesenteric lymph nodes; however, no quantitative changes in MDSCs were observed in the bone marrow. In contrast, gain-of-function TTP knock-in (TTPKI) mice had no change in MDSCs compared with control mice. Within the bone marrow, total granulocyte-monocyte progenitors (GMPs) and monocyte progenitors (MPs), direct antecedents of M-MDSCs, were significantly increased in both cTTPKO and TTPKO mice, but granulocyte progenitors (GPs) were significantly increased only in TTPKO mice. Transcriptomic analysis of the bone marrow myeloid cell populations revealed that the expression of CC chemokine receptor 2 (CCR2), which plays a key role in monocyte mobilization to inflammatory sites, was dramatically increased in both cTTPKO and TTPKO mice. Concurrently, the concentration of CC chemokine ligand 2 (CCL2), a major ligand of CCR2, was high in the serum of cTTPKO and TTPKO mice, suggesting that TTP impacts the mobilization of M-MDSCs from the bone marrow to inflammatory sites during aging via regulation of the CCR2-CCL2 axis. Collectively, these studies demonstrate a previously unrecognized role for TTP in regulating age-associated myelopoiesis through the expansion of specific myeloid progenitors and M-MDSCs and their recruitment to sites of injury, inflammation, or other pathologic perturbations.

Dataset Information

NLRP3/CCR2 Blockade by Arglabin and Its Derivative Suppresses Myeloid-Driven Immunosuppression and Potentiates Anti-PD-L1 Immunotherapy in Hepatocellular Carcinoma

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets